搜索
P531,1,2,1,1,1,1(:1.,710061;2.,710004):(hTERT)P53SP60101010hTERTP53hTERTP53(P0.05);hTERTP53(P0.05);hTERTP53(P0.05)hTERTP53,P53hTERT,;hTERTP53:(hTERT);P53;;:R736.1:A:167128259(2004)0520453203ClinicalandbiologicalsignificanceofhTERTandP53inthyroidcancerHuoXiongwei,MaQingyong,XuKangling,SunXuejun,LiuHao,CheXiangming,ShengWei(DepartmentofGeneralSurgery,FirstHospitalofXipanJiaotongUniversity,Xipan710061,China)ABSTRACT:ObjectiveTodetermineexpressionofhTERTandP53inthyroidcarcinomaanditsrelationshipwithdevelopmentandprognosisofthecarcinoma.MethodsAtotalof90samplesofthyroidtissues(60thyroidcarcinomas,10thyroidadenomas,10goitresand10normalthyroidtissues)werestudiedbySPimmunohistoche2micalmethod.ResultsThepositive2stainingratesofhTERTandP53werehigherinthyroidcarcinoma(P0.05).Thepositive2stainingratesofhTERTandP53werehigherincasesofundifferentiatedcarcinomas,positivemetastasislymphnodesorattumorstagesandthaninthecasesofwell2differentiated,nometastasislymphnodesorattumorstagesand(P0.05).TheexpressionofhTERTwassignificantlyrelatedwiththatofP53(P0.05).ConclusionOverexpressedhTERTandP53mayplayanimportantroleinthecarcinogenesisandpro2gressionofthyroidcarcinomaandhTERTexpressionisrelatedtoP53protein.ExaminationofexpressionofhTERTandP53proteinsmaybehelpfulinjudgingthebehaviorandprognosisofthyroidcancer.KEYWORDS:hTERT;P53;thyroidcarcinoma;immunohistochemistry:2004203222:2004206228:,Tel:85324009.:(19732),(),,,,:.,,,,PCR,,,,(SP)(hTERT)P5311.11990200260(21,19,12,8)21,39;2667,46.5,UICCTNM(19874):34,261010101.21.2.1hTERTP53SantaCruzBiotechnology255200410()JournalofXipanJiaotongUniversity(MedicalSciences)Vol.25No.5Oct.2004Inc;SPDABZymed1.2.240gL-1,,5m,SPP53hTERT150,hTERTP53,TBS1.2.3hTERTP53,5,5%(+)1.32,P0.0522.1hTERTP53hTERT;10.0%65.0%,(P0.05);P53,,53.3%(1)60hTERTP53(hTERT+/P53+)25,41.7%;hTERT+/P53-hTERT-/P53+35.0%(21/60);hTERT+/P53+hTERT-/P53-65.0%(39/60),2,hTERTP53(P0.05)1P53hTERTTable1ExpressionofP53andhTERTindifferentthyroidtis2suesTissuetypenP53+(%)-hTERT+(%)-Normalthyroidtissues100(0)100(0)10Goitres100(0)100(0)10Thyroidadenomas100(0)101(10.0)9Thyroidcarcinomas6032(53.3)2839(65.0)212.2hTERTP53hTERT55.0%91.7%,(P0.05),,(P0.05);hTERT81.5%51.5%,(P0.05);hTERT++52.9%80.8%,(P0.05)P5340.0%83.3%,(P0.01),,(P0.05);P5374.1%36.4%,(P0.005);P53++32.4%80.8%,(P0.005,2)2P53hTERTTable2ExpressionofP53andhTERTinthyroidcarcinomaVariablenP53+(%)-PhTERT+(%)-PTumortypeDifferentiated4016(40.0)2422(55.0)18PapillaryFollicular21198(38.1)8(42.1)13110.0510(47.6)12(63.2)1170.05Anaplastic1210(83.3)20.01311(91.7)10.053Medullary86(75.0)26(75.0)2LymphnodePositiveNegative273320(74.1)12(36.4)7210.00522(81.5)17(51.5)5160.05Histologicalgrading++342611(32.4)21(80.8)2350.00518(52.9)21(80.8)1650.05SexMaleFemale213914(66.7)18(46.2)7210.0516(76.2)23(59.0)5160.05Age4545293117(58.6)15(48.4)12160.0522(75.9)17(54.8)7140.053P0.05,3P0.01vs.differentiated454()25385%90%,()1hTERT,2,hTERT,hTERT3-5(TRAP),,hTERT,,hTERT,hTERT,,6,7,,hTERT,hTERT55.0%,91.7%(P0.05),,hTERThTERT,hTERT(+)(+)(P0.05),hTERT(P0.05),hTERT8P53,;P53,P53,P53,P53P5338.1%42.1%83.3%,P53,,P53P53,;P53(+)(+)P53;P539,10,,,,,,,P53,,,P53,,,11P53cDNA,P53cDNA1260P53hTERT,P53hTERT,P53hTERTP53hTERTP53hTERT,P53hTERT:[1]ShayJW,BacchettiS.AsurveyoftelomeraseactivityinhumancancerJ.EurJCancer,1997,33(5):787-791.[2WuA,IchihashiM,UedaM.CorrelationoftheexpressionofhumantelomerasesubunitswithtelomeraseactivityinnormalskinandskintumorsJ.Cancer,1999,86(10):2038-2044.[3LuzarB,PoljakM,MarinIJ,etal.Quantitativemeasurementoftelomerasecatalyticsubunit(hTERT)mRNAinlaryngealsquamouscellcarcinomasJ.AnticancerRes,2001,21(6A):4011-4015.[4LehnerR,EnomotoT,McGregorJA,etal.Quantitativeanal2ysisoftelomerasehTERTmRNAandtelomeraseactivityinen2dometrioidadenocarcinomaandinnormalendometriumJ.GynecolOncol,2002,84(1):120-125.[5HaraH,YamashitaK,ShinadaJ,etal.Clinicopathologicsig2nificanceoftelomeraseactivityandhTERTmRNAexpressioninnon2smallcelllungcancerJ.LungCancer,2001,34(2):219-226.[6OnodaN,IshikawaT,YoshikawaK,etal.TelomeraseactivityinthyroidtumorsJ.OncolRep,1998,5(6):1447-1450.[7AogiK,KitaharaK,BuleyI,etal.Telomeraseactivityinle2sionsofthethyroid:applicationtodiagnosisofclinicalsamplesincludingfine2needleaspiratesJ.ClinCancerRes,1998,4(8):1965-1970.[8ChengAJ,LinJD,ChangT,etal.Telomeraseactivityinbe2nignandmalignantthyroidtissuesJ.BrJCancer,1998,77(12):2177-2180.(474)5545,,,.P533,,(IGFs)3IGFs1957,,,,4IGF25,IGF2mRNA,IGF2Rutanen6IGF2mRNA,IGF2IImRNA,IGF2Tseng7,(1015d),IGF2IImRNA,(15d),IGF2mRNA,IGF2IGF2,IGF2Rutanae6,,IGF2IImRNA,18IGF2mRNA,IGF2,IGF2,,IGF2mRNA,IGF2mRNA,IGF2mRNAIGF2II,IGF2II,,(IUGR):[1],,.J.,1998,18(6):323-326.[2GaoJG,ZhuHH,FanJ,etal.Progestinandantiprogestindif2ferentiallyregulatetheexpressionofinsulin2likegrowthfactors(IGF2andIGF2)messengerribonucleicacidinhumanen2dometrialstromalcellsJ.BiolReprod,1995,53(2):355-360.[3HanVK,BassettN,WaltonJ,etal.Theexpressionofinsulin2likegrowthfactor(IGF)andIGF2bindingprotein(IGFBP)genesinthehumanplacentaandmembranes:evidenceforIGF2IGFBPinteractionatthefeto2maternalinterfaceJ